Crossmark

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples

Crossref DOI link: https://doi.org/10.1186/s12885-018-4594-0

Published Online: 2018-07-13

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vasmatzis, George http://orcid.org/0000-0002-3401-3497
Wang, Xue

Smadbeck, James B.

Murphy, Stephen J.

Geiersbach, Katherine B.

Johnson, Sarah H.

Gaitatzes, Athanasios G.

Asmann, Yan W.

Kosari, Farhad

Borad, Mitesh J.

Serie, Daniel J.

McLaughlin, Sarah A.

Kachergus, Jennifer M.

Necela, Brian M.

Thompson, E. Aubrey
Funding

Funding for this research was provided by:

Breast Cancer Research Foundation

Mayo Clinic, Center for Individualized Medicine
License Information

Text and Data Mining valid from 2018-07-13
More Information

Article History

Received: 15 February 2018

Accepted: 14 June 2018

First Online: 13 July 2018

Ethics approval and consent to participate

: All tumors specimens were obtained from the Mayo Clinic biobank and the study was performed under full Mayo Clinic Institutional Review Board approval (IRB# 07–005237) with written consent obtained from all patients.

: Not applicable.

: Sarah A. McLaughlin is a member of the editorial board (Associate Editor).

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.